Medication info
Januvia Tablets 100/15 mg (Sitagliptin, Pioglitazone)

Januvia Tablets 100/15 mg (Sitagliptin, Pioglitazone)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Phosphate Hydrate›128.5mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Light orange rectangular film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202302302 · Approved 2023.07.31 · Insurance code 671807760

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine may be administered as 1 tablet once daily, regardless of meals, to patients with type 2 diabetes mellitus receiving concomitant sitagliptin 100mg and pioglitazone 15mg or 30mg. Assessment of renal function is recommended before starting this medicine and periodically during treatment. -If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher, no dosage adjustment based on renal function is necessary. -Do not administer this medicine if the estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73m2.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug contains both sitagliptin and pioglitazone, helping to supplement dietary and exercise therapies for patients with type 2 diabetes. It effectively contributes to diabetes treatment by enhancing blood sugar management.

Dosage and Administration

Adult dosage

This medicine may be administered as 1 tablet once daily, regardless of meals, to patients with type 2 diabetes mellitus receiving concomitant sitagliptin 100mg and pioglitazone 15mg or 30mg. Assessment of renal function is recommended before starting this medicine and periodically during treatment. -If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher, no dosage adjustment based on renal function is necessary. -Do not administer this medicine if the estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73m2.

Precautions

This drug contains sitagliptin and pioglitazone, and there are precautions to be taken depending on each ingredient. First, sitagliptin can rarely cause serious allergic reactions. Such reactions may include hives, skin rash, difficulty breathing, and swelling of the face or neck; if these symptoms occur, it is important to stop taking the drug immediately and consult a doctor. Additionally, sitagliptin can cause acute pancreatitis, a condition where inflammation occurs in the pancreas, so if abdominal pain, vomiting, or loss of appetite arise during use, immediate medical attention is required. Pioglitazone can burden the heart and should not be used in patients with heart failure or a history of heart failure. If sudden weight gain or symptoms of heart failure such as edema or shortness of breath occur during treatment, it is essential to promptly inform medical personnel. Moreover, pioglitazone can cause fluid retention and exacerbate edema, so it is necessary to regularly check weight and edema status due to possible weight gain. This drug should not be given to patients with a history of bladder cancer or those with active bladder cancer. If blood or pain occurs during urination, it is critical to inform a doctor quickly. Patients with severely impaired kidney function should not take this drug, and those with slightly decreased kidney function may require dose adjustment, necessitating regular kidney function tests. Women who are pregnant or may become pregnant should not take this drug, and premenopausal women should use appropriate contraception while taking this medication. During treatment, hypoglycemic symptoms may occur, so if symptoms such as dizziness, cold sweat, or severe fatigue arise, blood sugar levels should be checked and appropriately managed. Liver function abnormalities may occur while taking this medication, so if symptoms like fatigue, jaundice, or changes in urine color appear, prompt medical evaluation is necessary, and regular liver function tests are recommended. Some patients may experience arthralgia or skin disorders, so any new pain or skin changes should be reported to medical personnel. Finally, this drug may interact with other medications, so if other drugs are being taken, it is vital to inform medical personnel and to follow the doctor's instructions regarding administration.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • congestive heart failure
  • fluid retention
  • edema
  • hypoglycemia
  • upper respiratory infection
  • rhinitis
Show 72 more
  • headache
  • diarrhea
  • nausea
  • constipation
  • vomiting
  • severe arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight gain
  • urinary tract infection
  • low back pain
  • dizziness
  • abdominal distension
  • elevated serum creatine kinase
  • hypertension
  • heart failure
  • limb pain
  • chest pain
  • fracture
  • decreased vision
  • diabetic macular edema
  • liver failure
  • worsening liver disease
  • loss of appetite
  • upper abdominal pain
  • fatigue
  • weakness
  • dyspnea
  • itching
  • chest pain
  • tremors
  • chills
  • gastrointestinal disease
  • epigastric discomfort
  • numbness
  • muscle stiffness
  • head discomfort
  • urticaria
  • eczema
  • arthralgia
  • knee abnormality
  • arm weakness syndrome
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • blurred vision
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • cardiac function loss

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a container that blocks light and air, and humidity should be avoided. A storage temperature between 15 and 30 degrees Celsius is appropriate.

Appearance and packaging

Appearance

Light orange rectangular film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.